NEW YORK, Dec. 9, 2021 /PRNewswire/ — CB Insights today named Sweetch, a digital therapeutics innovator and creator of the hyper-personalized engagement platform for chronic conditions, to its third annual Digital Health 150, which showcases the 150 most promising private digital health companies in the world. This year’s Digital Health 150 was unveiled live during CB Insights’ annual Future of Health event.
The 2021 Digital Health 150 cohort has raised roughly $14.9B in aggregate funding across 522 deals since 2016, and includes startups at various investment stages of development, from early-stage to well-funded unicorns. Companies this year include startups working on data integration & analytics, hybrid virtual / in-person care, digital therapeutics, clinical intelligence, and more.
“This year’s Digital Health 150 is one of our most expansive yet, spotlighting 16 categories including virtual care, clinical trials tech, and workflow automation, as well as adding new categories such as home health tech and computer-aided imaging,” said Brian Lee, SVP of CB Insights’ Intelligence Unit. “Last year’s class has seen more than 20 exits, raised an additional $18.6B in aggregate funding, and announced over 250 partnerships since being recognized, and we’re excited to see the future success of this year’s winners.”
“We are honored to be recognized among these great innovators in digital health as we continue our mission to positively impact the lives of people living with chronic conditions and global healthcare economics,” said Yoni Nevo, CEO of Sweetch. “Sweetch is proud to be providing the rapidly evolving remote health space with a critical missing component – effective, continuous relationships between health ecosystem players and all the individuals they serve, at scale.”
Through an evidence-based approach, the CB Insights research team selected the Digital Health 150 from a pool of over 11,000 companies, including applicants and nominees. They were chosen based on several factors, including data submitted by the companies, company business models and momentum in the market, and Mosaic scores, CB Insights’ proprietary algorithm that measures the overall health and growth potential of private companies.
Providing a hyper-personalized, scalable and cost-effective solution, Sweetch increases patient adherence across various aspects of disease management and improves clinical outcomes for people with chronic conditions. The company is the first to combine AI and EI (emotional intelligence) to learn patients’ real-life behavior patterns and optimize engagement. Its proprietary Just-in-Time-Adaptive-Intervention (JITAI) technology converts millions of data points originating from an individual’s smartphone and other connected devices into hyper-personalized recommendations in just the right tone, time and real-world context to catalyze long-term behavior change as part of their daily routine.
About CB Insights
CB Insights builds software that enables the world’s best companies to discover, understand, and make technology decisions with confidence. By marrying data, expert insights, and work management tools, clients manage their end-to-end technology decision-making process on CB Insights. To learn more, please visit www.cbinsights.com.
CB Insights Press Contact:
Sweetch is the developer of hyper-personalized engagement solutions for chronic conditions.
Sweetch is the first behavioral science company to leverage AI and EI (emotional intelligence) enabling pharmaceutical companies, device manufacturers, payers, and healthcare providers to build continuous relationships and engage with every individual patient with chronic conditions, at scale. Sweetch provides a clinically validated digital therapeutics platform that moves individuals to achieve micro-goals with hyper-personalized recommendations in the right time, tone, and real-world context every step of the way throughout their health journey. Analyzing every user’s personality, behavior, and context, Sweetch’s proprietary algorithms identify the individual’s compliance patterns and continuously adapt recommendations to each user, leading to significantly improved adherence to treatment programs, better long-lasting health outcomes and improved healthcare economics. Sweetch is HIPAA and GDPR compliant.
For more information, visit https://sweetch.com/
FINN Partners for Sweetch
+1 929 588 2016